BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

TAIPEI--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new ...

Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...

US$46 million investment to establish wholly owned Puerto Rico subsidiary supporting U.S. manufacturing, supply security, and long-term growth of BESREMi (R) (ropeginterferon alfa-2b) Company plans to ...

Please provide your email address to receive an email when new articles are posted on . Ropeginterferon alfa-2b — a next generation, mono-pegylated interferon alfa-2b isoform — administered once every ...

ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate ...

In the SURPASS-ET trial, ropeginterferon alfa-2b outperformed anagrelide for high-risk essential thrombocythemia patients ...

BESREMi ® recognized by National Comprehensive Cancer Network ® (NCCN ®) as an appropriate substitute for Pegasys ® in the face of ongoing supply limitations BURLINGTON, Mass., March 04, ...

Review of studies published in Frontiers in Oncology highlights dosing considerations that may help more patients achieve earlier complete hematological response BURLINGTON, Mass.--(BUSINESS ...

Wien/Atklanta (pts021/11.12.2017/13:30) * High rates and durable Clinical and Hematological response were achieved with Ropeginterferon alfa-2b at 24 months of treatment * The disease modifying ...

Vienna, 17th of December 2018: AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that EMA´s CHMP adopted a positive opinion for approval of Ropeginterferon alfa-2b/BESREMi® indicated as ...